Table 1.
Description of the current situation, simulation 1 and simulation 2.
| Single agent chemotherapy (SAC) |
Compilation chemotherapy (CC) |
|||||
|---|---|---|---|---|---|---|
| Patent trastuzumab | SC trastuzumab | Biosimilar trastuzumab | Patent trastuzumab | SC trastuzumab | Biosimilar trastuzumab | |
| Current situation | 2.1 % | 77.7 % | 20.2 % | 7.0 % | 39.9 % | 53.1 % |
| Simulation 1 | 2.1 % | 77.7 % | 20.2 % | 0.0 % | 0.0 % | 100.0 % |
| Simulation 2 | 0.0 % | 100.0 % | 0.0 % | 0.0 % | 0.0 % | 100.0 % |